ArticleJAAD case reports2021
Relapsing-remitting multiple sclerosis arising in a patient with atopic dermatitis on dupilumab.
Article in JAAD case reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 11 citations in OpenAlex.
- Safety and Effectiveness Profile of Dupilumab in the Treatment of Atopic Dermatitis in Special Populations.Acta dermato-venereologica · 2025Observational
- Dupilumab, a Novel Treatment for Peripheral Neuropathy: A Case Series.Dermatology and therapy · 2025Article
- Managing Atopic Dermatitis with Dupilumab in Special Populations: A Case Series Study.Clinical, cosmetic and investigational dermatology · 2025Article
- Two-sample Mendelian randomization analysis of causal relationship between eczema and autoimmune diseases.Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2024Article
- Effect of Dupilumab on Generalized Verrucosis in Refractory Bullous Pemphigoid.Acta dermato-venereologica · 2023Article
- Ellagic acid effects on disease severity, levels of cytokines and T-bet, RORγt, and GATA3 genes expression in multiple sclerosis patients: a multicentral-triple blind randomized clinical trial.Frontiers in nutrition · 2023Article
- Dupilumab in patients with moderate to severe atopic dermatitis and multiple sclerosis.JAAD case reports · 2023Article
- Onset of multiple sclerosis in a patient on dupilumab therapy for atopic dermatitis: A case report.Dermatologic therapy · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.